Everyone told me that SSF is working on the next layoff. They all said Nov is the month. Too many oncology and RA TAMs. Anyone knows the specifics?
I am dying to find out what kind of BS they would come up with this time around. Do you have a soul? That would get rid of everyone in management! The mindset thing was the corniest and lamest thing I have ever heard in my life. It would have been funny if it wasn't so sinister.
Heard from a reliable source that during the next assessment of field teams, they will also try to shave off the placed teams. RA and Onc + Skin, Hem, Ophth, Neuro. New requirements for ICs outside ecosystems and additional expansion of roles. Probably won’t start until Q1’21. Good luck All.
All signals say yes since placed and access is nonexistent or can be handled as house accounts or by HDs.
Whoever posted this seems to be close to the source. Basel has been monitoring the impact from the lock-down. I just heard that a number of ZS people were on the call last week. It is usually not a good sign when they are involved. I learned that so far the data supports the acceleration of the further reduction in oncology, RA and Hem. The ocre and skin teams are next. ZS's data also suggests that some HD's and field marketing in some ecosystems will also be on the chopping board. I have no skin in the game. I am in sales ops. The numbers, forecast and payers are not looking good with the biosimilars, patent cliff and competitions. It feels like we just don't have an answer for any of these. None of the people above me has any accountability or sense of urgency. It is very weird to work here these days. It is like they are all giving up and going to leave soon. The doomsday is around the corner. Thought you guys out in the field need to know. The morale in SSF is absolutely dreadful. We are running out of people to support. I guess my job will likely be gone by next year. Best of luck.
Whoever posted this seems to be close to the source. Basel has been monitoring the impact from the lock-down. I just heard that a number of ZS people were on the call last week. It is usually not a good sign when they are involved. I learned that so far the data supports the acceleration of the further reduction in oncology, RA and Hem. The ocre and skin teams are next. ZS's data also suggests that some HD's and field marketing in some ecosystems will also be on the chopping board. I have no skin in the game. I am in sales ops. The numbers, forecast and payers are not looking good with the biosimilars, patent cliff and competitions. It feels like we just don't have an answer for any of these. None of the people above me has any accountability or sense of urgency. It is very weird to work here these days. It is like they are all giving up and going to leave soon. The doomsday is around the corner. Thought you guys out in the field need to know. The morale in SSF is absolutely dreadful. We are running out of people to support. I guess my job will likely be gone by next year. Best of luck.
My source said they’ll be handled like any other health system or national account. Kaiser/VA/DoD are generally transactional interactions for contracting that don’t require FAMs or account managers. COVID lock outs have made this more clear. Ecosystems can manage local needs and communications when needed. Sorry to be the bearer of bad news. They’re gutting us like fish.
Thank you. Any idea on timing? I’ve seen November and Q1 mentioned. Despite AH shooting the rumors down on the last CMG call, I still believe these cuts are coming, and soon.
they are hiring Kaiser Account people. Don’t they know there is NO ACCESS...especially from GEnentech?
I can confirm that there will be cuts before yearend. 2021 is shaping up to be a difficult year with greater biosimilar impact than we thought. No numbers have yet been discussed (to my knowledge) but it’s not a question of if or when - it’s a question of how deep at this point.
I hear, Genentech is looking to sell off a few things to lessen the losses. That could turn into Genentech being sold by making the bottom line look better.
Neuro is safe. We are currently buying more products and investing heavily in that franchise. They already went through Transformation, and laid off people even after the most successful product launch in industry history. That should have clued the rest of you in. In most ecosystems there are very few. Some may be heavy, but if you are in a an ecosystem with 3 or under you are ‘probably” safe. The real tragedy was how can a company pirate tenured successful reps from competitors and after the most successful product launch in history, dispose of them while the product is sky rocketing and paying for everyone else?
They can’t touch ophthalmology, we’re too lean and too valuable to cull out with the future launch of port delivery. Lucentis will have a second life and bring in gobs of $$$ for the Swiss. With Novartis pooping their pants, there’s another life for us
blah blah blah. Most successful launch in history. Blah blah blah. They realized Ocrevus was selling itself and they didn’t need you. When they adjust ecosystem lines they’ll find a way to trim more MS fat.
This person is close to source. Everything is on table behind the scenes but AH doesn’t want rumors to get out before announcement so he is significantly narrowing circle of trust, including keeping some of his directs in dark. It’s strictly need to know. AH is pissed rumors swirling before he had even before evaluation and decision made. It’s likely that the rumors and info leaks will slow down But AH implements countermeasures. But make no mistake, it’s the calm before the storm!
